2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, Translational Research, MDS, MPN, CML, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2512 Post-transplant rather than pre-transplant TP53 variant allele frequency predicts outcomes after allogeneic transplant in MDS and AML: An ultra-sensitive NGS analysis

Sameeran Das, Feng Gao, MD, PhD, MPH, MS2, John F. DiPersio, MD3, Geoffrey L. Uy, MD4, Samuel Urrutia, MD, MS5, Meagan A. Jacoby, MD, PhD6, David H Spencer, MD, PhD7, Eric Duncavage, MD8, Keith Stockerl-Goldstein, MD9, Ramzi Abboud, MD10
1 Washington University School, Saint Louis, Missouri, United States
2 Washington University School, Saint Louis, Missouri, United States
3 Washington University School, Saint Louis, Missouri, United States
4 Washington University School, Saint Louis, Missouri, United States
5 Washington University School, Saint Louis, Missouri, United States
6 Washington University School, Saint Louis, Missouri, United States
7 Washington University School, Saint Louis, Missouri, United States
8 Washington University School, Saint Louis, Missouri, United States
9 Washington University School, Saint Louis, Missouri, United States
10 Washington University School, Saint Louis, Missouri, United States

Introduction:
Patients with TP53-mutated MDS and AML face dismal outcomes even after allogeneic hematopoietic stem cell transplant (alloHCT). The role of molecular disease burden-driven assessment remains unclear. Prior next-generation sequencing studies have been bound to a limit of detection (LOD) of 2% variant allele frequency (VAF). Myeloseq, Washington University’s clinical NGS panel, now achieves an LOD of 0.1% for previously detected variants. With this ultra-sensitive assay, we studied the prognostic value of TP53 VAF pre- and post-transplant in a single-institution cohort of MDS and AML patients.

Methods:
We retrospectively analyzed 91 adults with TP53-mutated MDS or AML who underwent alloHCT at Siteman Cancer Center between 2018 and 2026 and had a diagnostic NGS. Pre-HCT Myeloseq was available in 90 patients; post-HCT Myeloseq was available in 56 at day +30 and in 61 at day +100. VAF was modeled as a continuous variable as it satisfied linearity; hence, hazard ratios (HR) reflected the risk of an outcome per 1% change in VAF. Univariate and multivariable Cox regression models assessed overall survival (OS) and relapse-free survival (RFS). Fine-gray models treated non-relapse mortality (NRM) as a competing event to relapse. Landmark analyses for post-HCT VAF excluded patients with follow-up shorter than the landmark timepoints.

Results:
The median age of the cohort was 61 years; 65.9% had AML and 34.1% had MDS; and 52.4% had biallelic/multi-hit TP53 status. Donor types included matched unrelated (42.9%), haploidentical (40.7%), and matched related (16.5%). Most patients received myeloablative conditioning (75.8%). Median VAF at diagnosis was 41% and median pre-HCT VAF was 11.5%. Myeloseq’s LOD was 0.1% in 25.3% of patients, 0.25% in 22.0%, and 2% in 52.7%, the latter representing transplants before the utilization of the high-sensitivity Myeloseq. Median follow-up time was 248 days (range 6-2245); 57% relapsed. 

Pre-HCT TP53 VAF was not prognostic as a continuous variable (OS HR 1.007, p=0.107; RFS HR 1.007, p=0.092). Diagnostic VAF was significant univariately (OS p=0.045; RFS p=0.022) but lost significance after adjustment for donor type (OS p=0.151; RFS p=0.1025), suggesting a confounding effect of transplant characteristics. Neither multi-hit status (OS p=0.810) nor conditioning intensity (OS p =0.884) was significant for outcome.

In contrast, post-HCT TP53 VAF demonstrated highly significant prognostic value at day +30 and day +100 landmarks. Day +30 VAF predicted OS (HR 1.041, p=0.0002) and RFS (HR 1.034, p=0.0006) and remained significant after adjusting for donor type (OS HR = 1.040, 95% CI 1.017-1.064, p=0.0006; RFS HR 1.032, 95% CI 1.012-1.053, p=0.0019). Day +100 VAF was the strongest predictor for OS (HR 1.039, p<0.0001) and RFS (HR 1.035, p<0.0001) and was associated with relapse in competing risks (HR 1.030, 95% CI 1.019-1.041, p<0.001), while day +30 VAF was not (HR 1.000, 95% CI 0.980-1.021, p=0.962).

Conclusions:
Post-transplant Myeloseq independently predicts outcomes in TP53-mutated MDS and AML. Quantitative, continuous VAF also outperforms binary MRD detection status, supporting the role of ultra-sensitive reporting instead of threshold-based reporting. Pre-HCT disease burden measured using a more sensitive assay than prior studies did not predict outcome, arguing against deferring transplant to achieve a deeper molecular remission. Our findings support post-transplant MRD as a guide for intervention strategies in TP53-mutated MDS and AML.

Sameeran Das: No relevant conflicts of interest to declare.